P

PLx Pharma Inc
F:1D5A

Watchlist Manager
PLx Pharma Inc
F:1D5A
Watchlist
Price: 0.0005 EUR
Market Cap: 210k EUR

Net Margin
PLx Pharma Inc

-606.9%
Current
-13 847%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-606.9%
=
Net Income
-27.6m
/
Revenue
4.5m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
PLx Pharma Inc
F:1D5A
210k EUR
-607%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
491.8B USD
27%
CH
Roche Holding AG
SIX:ROG
271.5B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP
16%
US
Merck & Co Inc
NYSE:MRK
274.9B USD
30%
CH
Novartis AG
SIX:NOVN
218.4B CHF
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
144.9B USD
16%
No Stocks Found

PLx Pharma Inc
Glance View

Market Cap
210k EUR
Industry
Pharmaceuticals

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.

1D5A Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-606.9%
=
Net Income
-27.6m
/
Revenue
4.5m
What is the Net Margin of PLx Pharma Inc?

Based on PLx Pharma Inc's most recent financial statements, the company has Net Margin of -606.9%.

Back to Top